FUTURE OF HEALTHCARE
GeneQuantum Healthcare | April 19, 2022
GeneQuantum Healthcare Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic antibody drug conjugate (ADC). Aimed Bio, a spin-off company from Samsung Medical Center, is focusing on developing innovative antibody-centric drugs for brain diseases with few treatment options. Additional details were not disclosed.
GeneQuantum focuses on next generation Antibody Drug Conjugate development. Taking advantage of the proprietary 'Ligase Dependent Conjugation' technology platform, which allows a site-specific conjugation of cytotoxins or other type of payloads to antibodies, the company has successfully developed a robust pipeline with more than 10 assets, with several at or approaching clinical stage. In addition to expanding the unique technology platform, the company has entered into a number of partnerships with domestic biotech/pharmaceutical companies and international partners. The growing number of partnerships speaks to the power of the GeneQuantum platform technology for not only improving key therapeutic characteristics of existing molecules, but also for creating new classes of molecules, ultimately increasing the number of available treatment options for patients worldwide. GeneQuantum is excited about the significant potential of partnerships with business partners and will continue to expand its deal pipeline in the antibody drug conjugate and protein therapeutic market.
The collaborating ADC is a first-in-class asset with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect. The resulting ADC is expected to treat brain and other cancers with huge unmet needs.
"As an innovative antibody+ company, we look for complementary partners to maximize value of our platform technology. Aimed Bio not only has differentiated antibody acting on a unique target but also has deep knowledge and expertise in the field of brain tumor & CNS diseases. This collaboration is based on an excellent match between the two companies to generate a FIC ADC. Through close partnership, we are thrilled to bring revolutionary therapy for those patients without efficient treatment at this moment."
Dr. Gang Qin, the Founder & Chairman, CEO of GeneQuantum
Dr. Dohyun Nam, the Founder & Chairman, CTO of Aimed Bio and internationally renowned neurosurgeon with 32 years of experience in brain tumor & CNS diseases commented: "Aimed Bio has been successfully expanding its R&D pipeline for the past 2 years, and I am pleased to start this collaboration with GeneQuantum. After evaluating the data, the linker-payload and conjugation technology GeneQuantum provides proved to be very safe and effective. With the best antibody and brain tumor expertise of Aimed Bio, I believe the collaborating ADC will bring a tremendous impact on the field. We look forward to initiating clinical trial as soon as possible."
About GeneQuantum Healthcare Co., Ltd.
GeneQuantum Healthcare Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutics. The company is focused on the development of a next generation of bioconjugate therapeutics to meet the unmet medical needs of cancer patients globally. For more information, visit www.genequantum.com.
About AIMEDBIO Inc.
AIMEDBIO is a spin-off company from Samsung Medical Center established in August 2018. AIMEDBIO aims to provide therapeutic solutions to patients with serious brain diseases, including neuro-oncological and -degenerative diseases, to save patients' lives and improve patients' quality of life. Based on solid global networks with key opinion leaders in the field, an excellent research team with profound achievements, and R&D pipelines with an outstanding drug development platform, AIMEDBIO is an emerging leader for development of innovative therapeutics against diverse brain diseases.
Read More
AI
TapCloud | January 28, 2022
TapCloud, a technology leader in patient-directed care, will partner with Maxwell Healthcare Associates (MHA), a leading post-acute operational, financial, technological and regulatory consulting firm, to transform the post-acute industry with their innovative patient communication and artificial intelligence (AI) solution.
TapCloud's technology uses AI-driven tools to capture symptoms that automatically identify patients in need. The system supplies patients or their caregivers with words to indicate how they're feeling. The word cloud symptom tracker is unique to the patient, their-conditions, their medications and their history as it learns and evolves each time they use it.
MHA's reach and influence within the post-acute space is expansive, and their unique ability to connect industry partners with strategic solutions continues as they ally with TapCloud. They integrate result-orientated products and services to post-acute organizations that seek immediate answers for their problems. With MHA's organizational expertise and TapCloud's advanced solution, home health, palliative, and hospice providers will have the necessary tools to improve end-of-life care.
"We're very excited about 2022 and the opportunities that it will present us. TapCloud is an extraordinary organization that will enhance the care and communication with patients in the post-acute setting. Our goals at MHA are to equip our customers with tools that will not only enhance the care they provide but expose them to tools that have been vetted through our review process."
CEO of Maxwell Healthcare Associates,Jennifer Maxwell
President of TapCloud,Jolinda Lambert, shares in the enthusiasm and strongly believes the partnership will blossom into the new year. "Our product's ability to change how care is delivered is transformative. We can't wait to get started with MHA to help shape personalized care."
About TapCloud
TapCloud is aChicago-based health-tech company founded in 2013. They produce an AI-driven application that provides better insights into a patient's symptoms and automatically identifies patients in need at the right time.
About Maxwell Healthcare Associates
Maxwell Healthcare Associates boasts an average of 20 years of experience in the post-acute space and has a pulse on what's relevant now in the industry. MHA can work with home health and hospice agencies to strategize, optimize and transform agencies across the nation.
Read More
FUTURE OF HEALTHCARE
Modivcare Inc. | May 19, 2022
Modivcare Inc. a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, announced the Company’s Remote Patient Monitoring Segment has acquired Guardian Medical Monitoring, LLC from its parent company, Guardian Alarm.
Guardian Medical Monitoring is a leading provider of remote patient monitoring solutions to Managed Care Organizations and state Medicaid payors including Personal Emergency Response Systems and medication management. GMM’s RPM platform currently monitors approximately 50,000 aging and chronically ill patients on behalf of their respective payors.
“Remote patient monitoring is essential to Modivcare’s mission to connect patients to care through our integrated supportive care platform. Our comprehensive remote patient monitoring offering allows patients to safely age in their homes with technology-enabled connectivity to care which increases patient engagement and reduces costs. We are excited to accelerate the growth of Modivcare’s RPM Segment with the acquisition of GMM, and we are excited to welcome the GMM team to Modivcare.”
Daniel E. Greenleaf, Modivcare’s President and Chief Executive Officer
Jason Anderson, President, Modivcare Home added, “Guardian Medical Monitoring is a complementary acquisition for Modivcare’s RPM Segment, strengthening our customer relationships and expanding our service footprint across key states. Additionally, this acquisition provides an opportunity to expand our E3 engagement platform across a larger base of members and payors. Modivcare’s E3 platform helps our partners reduce gaps in care and address social determinants of health by engaging, educating, and empowering members using our proprietary platform.”
About Modivcare
Modivcare Inc. is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation, personal care and remote patient monitoring.
Read More
HEALTH TECHNOLOGY
Kareo | April 04, 2022
Dr. Daniel Spriggs, a long-time Kareo user at his former practices, chose to continue using the integrated platform for his new practice the Perdido Bay Medical Group because of its functionality, familiarity, and ease of use. Dr. Spriggs was previously part of other medical groups, and so he needed to develop a new online identity when he opened his new practice. In the first 60 days following implementation, PatientPop’s solution improved the practice’s visibility online garnering over 1,500 new website visitors. Simultaneously, PatientPop helped solidify 70 new patient reviews with an average of 5 out of 5-star ratings. Improving the practice website’s SEO brought in over 500 organic website connections.
“Kareo’s platform has allowed me to create workflows that mimic how I work, making it easier for me to deliver care to my patients. It was still the best choice when it came to a solution for my new practice. Even though I haven’t used PatientPop for very long, it has already improved my website performance greatly by making my brand presence more cohesive and is helping to bring in new patients. It's a tremendous benefit that Kareo and PatientPop have merged because I don’t have to rely on disparate systems which are often confusing, not as fiscal, and don’t deliver the best results.”
Dr. Spriggs
Kareo and PatientPop announced theymerged in 2021to form Tebra. The combined company’s mission is to equip independent practices with digital tools to deliver modernized care. The all-in-one solution can help providers support and attract new patients, get paid quickly, and operate more efficiently.
“Tebra’s all-in-one platform is unlocking better healthcare for small practices to modernize care delivery and improve the patient experience,” Andrea Kowalski, Senior Vice-President of Product for Kareo, said. “Our partnership with the Perdido Bay Medical Group illustrates our ability to tailor solutions to what is most important to our client’s needs. We will continue to enhance and simplify our solutions to drive practice transformation.”
About the Perdido Bay Medical Group
The Perdido Bay Medical Group is a family medicine practice serving adults of all ages and children as young as four years old in Lillian, Alabama. Experienced family medicine physician Daniel Spriggs, MD, launched the practice in 2021 when he discovered that the Lillian community needed more than the ordinary family medicine practices. The Perdido Bay Medical Group offers chronic disease management, acute illness care, arthritis care, geriatrics, and specialized care for disability and special-needs patients.
About PatientPop
PatientPopis an industry leader in practice growth technology with a platform that helps thousands of providers promote their practice, attract and acquire patients, and retain them, for a thriving business. The integrated platform eases and enhances the patient journey from start to finish, with a streamlined digital workflow that significantly reduces work for providers and staff. PatientPop has been recognized with many industry awards and accolades, including the Inc. 500, Deloitte Fast 500, Entrepreneur 360, Consumer World Awards, Capterra Shortlist, G2 Leader, and Silicon Review 50 Fastest Growing Companies. PatientPop has headquarters in Santa Monica, California.
About Kareo
Kareois a cloud-based healthcare technology platform built to meet the unique needs of independent practices in dozens of specialties. Today, Kareo helps over 80,000 providers in 50 states deliver outstanding patient care and run more efficient and profitable practices. The Kareo technology platform helps providers find more patients, manage patient care with a fully certified and easy-to-use EHR, and get paid quickly within a unified, easy-to-use solution. Kareo has received extensive industry recognition, including the2021 Best in KLAS award for Small Practice Ambulatory EMR/PM Solutions, the Deloitte Technology Fast 500, Inc. 5000, and a ranking at the top of Gartner’s Leader Quadrant in the FrontRunners Software Analysis of EHR. Kareo’s headquarters are based in Irvine, California.
Read More